KPC Pharmaceuticals

KPC Pharmaceuticals EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of KPC Pharmaceuticals (600422.SS) as of Nov 4, 2026 is 473.56 M CNY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 1.05 B CNY — a change of -55.11% (lower).

EBITDA

473.56 MCNY

YoY

-55.11%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of KPC Pharmaceuticals is 2025 473.56 M CNY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of KPC Pharmaceuticals was 2024 1.05 B CNY. It decreases by -55.11% lower compared to the previous year.

The KPC Pharmaceuticals EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
478.11 M CNY
Jan 1, 2019
643.35 M CNY
Jan 1, 2020
617.33 M CNY
Jan 1, 2021
735.18 M CNY
Jan 1, 2022
624.25 M CNY
Jan 1, 2023
888.04 M CNY
Jan 1, 2024
1.05 B CNY
Jan 1, 2025
473.56 M CNY
The KPC Pharmaceuticals EBITDA history
YEAREBITDAYoY
473.56 MCNY-55.11%
1.05 BCNY+18.78%
888.04 MCNY+42.26%
624.25 MCNY-15.09%
735.18 MCNY+19.09%
617.33 MCNY-4.04%
643.35 MCNY+34.56%
478.11 MCNY+1.65%
470.33 MCNY-1.05%
475.33 MCNY-3.16%
490.82 MCNY+39.50%
351.85 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

KPC Pharmaceuticals Stock analysis

What does KPC Pharmaceuticals do? KPC Pharmaceuticals, Inc. generates revenue through the research, development, manufacturing, and international marketing of its diverse drug portfolio. The company sells natural herbal medicines, traditional Chinese medicines, and chemical synthetic drugs, including central nervous system drugs, cardiovascular and cerebrovascular drugs, anti-parasitic drugs, anti-microbial drugs, anti-gout drugs, hormones and endocrine drugs, hemorrhoids medicines, and anti-inflammatory drugs. Its main customers are healthcare providers, hospitals, and pharmaceutical distributors globally. The firm also produces health products and offers medical services as additional revenue streams. The company's product segments are defined by therapeutic categories such as central nervous system treatments, cardiovascular care, and anti-inflammatory solutions. These products target both domestic and international markets, with a focus on traditional Chinese medicine and natural herbal formulations. Sales are driven by wholesale distribution networks and direct commercial partnerships in the pharmaceutical industry. KPC Pharmaceuticals' revenue model combines product sales from its core drug lines with supplementary health product offerings and medical service provision. The business leverages its manufacturing capabilities in Kunming, Yunnan to serve global markets, with a strong emphasis on traditional Chinese medicine and natural herbal medicine segments. The firm's international marketing efforts support its presence in multiple regions. KPC Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about KPC Pharmaceuticals stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of KPC Pharmaceuticals is 473.56 M CNY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of KPC Pharmaceuticals changed from 1.05 B CNY to 473.56 M CNY, representing a -55.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) KPC Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KPC Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — KPC Pharmaceuticals

All Key Metrics — KPC Pharmaceuticals